全部 |
  • 全部
  • 题名
  • 作者
  • 机构
  • 关键词
  • NSTL主题词
  • 摘要
检索 二次检索 AI检索
外文文献 中文文献
筛选条件:

1. Innovative Therapies for Acquired Hemophilia A NSTL国家科技图书文献中心

Franchini, Massimo |  Focosi, Daniele -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 68~72 - 共5页

摘要:Acquired hemophilia A (AHA) is a rare |  autoimmune bleeding disorder which can be life-threatening | . AHA is due to autoantibodies against coagulation |  factor VIII. Disease onset may be idiopathic |  (approximately half of the cases) or triggered by autoimmune
关键词: acquired hemophilia A |  bleeding |  rituximab |  emicizumab

2. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice NSTL国家科技图书文献中心

Shimizu, Kazuki |  Nakajima, Yuto... -  《Thrombosis and Haemostasis》 - 2025,125(1) - 21~32 - 共12页

摘要: breakthrough bleedings in patients with hemophilia A with |  emicizumab-treated patients with hemophilia A (PwHA). To | Background Bypassing agents are used for |  inhibitor (PwHAwI) receiving emicizumab prophylaxis | . Previous study demonstrated a weak binding affinity
关键词: FVIII |  FVIII inhibitor |  coagulation |  hemophilia |  hemostasis

3. Five decades of successive establishment of hemophilia care in Thailand NSTL国家科技图书文献中心

Chuansumrit, Ampaiwa... |  Sriphaisal, Thip... -  《Expert review of hematology》 - 2025,18(4) - 309~321 - 共13页

摘要: hemophilia in healthcare resource limited countries is |  patients with hemophilia initially received episodic | IntroductionManagement of patients with |  challenging for healthcare providers.Area coveredThai |  treatment of cryoprecipitate and fresh frozen plasma (FFP
关键词: Hemophilia |  replacement therapy |  early bleeding treatment |  prophylaxis |  national advocacy

4. Non-factor Therapies for Hemophilia: Achievements and Perspectives NSTL国家科技图书文献中心

Jimenez-Yuste, Victo... -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 23~27 - 共5页

摘要: management of hemophilia A with inhibitors, offering a |  for patients with hemophilia B with inhibitors and |  other hemophilia subtypes. Administered subcutaneously |  long half-life, which can shift severe hemophilia |  potential of NFTs in treating persons with hemophilia.
关键词: hemophilia |  non-factor replacement therapies |  FVIII mimetics |  rebalancing agents

5. Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives NSTL国家科技图书文献中心

Bala, Natasha S. |  Thornburg, Courtney ... -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 28~40 - 共13页

摘要: with hemophilia include development of long-acting |  endogenous production of factor VIII (FVIII) in hemophilia | Strides in advancements of care of persons |  factor replacement therapies, novel substitution and |  hemostatic rebalancing agents, and most recently approved
关键词: hemophilia A |  gene therapy |  valoctocogene roxaparvovec

6. Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes NSTL国家科技图书文献中心

Dolan, Gerard |  Fijnvandraat, Karin... -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 58~67 - 共10页

摘要:People with nonsevere hemophilia (PWNSH) are |  phenotypically more diverse than those with severe hemophilia |  hemophilia have largely focused on severe disease and, as a |  improvement in phenotype for people with severe hemophilia |  hemophilia, it is timely to review the aspects of nonsevere
关键词: disease management |  factor VIII |  factor IX |  hemophilia A |  hemophilia B

7. Problems faced by people with hemophilia aged 18-35 years in social life: a qualitative study NSTL国家科技图书文献中心

Davun, Selin |  Altas, Zeynep Meva... -  《Expert review of hematology》 - 2025,18(3) - 249~256 - 共8页

摘要: people with hemophilia aged 18-35 years in their social |  research, 13 individuals aged 18-35 years with hemophilia |  encountered in various fields related to hemophilia using a |  out.ResultsMost participants were diagnosed with hemophilia in |  condition since then. Hemophilia-related complications
关键词: Hemophilia |  social life |  symptoms |  healthcare |  stigma

8. The Evolution of Hemophilia Pharmacological Treatments and Therapeutic Targets at the Turn of the Third Millennium NSTL国家科技图书文献中心

Coppola, Antonio |  Zani, Matteo... -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 10~17 - 共8页

摘要: hemophilia, the congenital X-linked hemorrhagic disorder |  (hemophilia A) or FIX (hemophilia B), has been the |  currently considered the gold standard of hemophilia |  allowed clinicians operating at hemophilia treatment |  hemophilia, improving outcomes, adherence to therapy, and
关键词: factor concentrates |  health equity |  hemophilia |  management |  non-replacement treatment |  prophylaxis

9. Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives NSTL国家科技图书文献中心

Castaman, Giancarlo |  Miesbach, Wolfgang -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 41~48 - 共8页

摘要:Hemophilia B is the first bleeding disorder |  hemophilia B has the potential to provide long-term |  for which gene therapy clinical programs began | . Presently, adenovirus-associated vectors represent the |  best means to deliver the transgene, and their
关键词: hemophilia B |  gene therapy |  factor IX |  adenovirus-associated vector |  FIX-Padua

10. Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives NSTL国家科技图书文献中心

Mancuso, Maria Elisa -  《Seminars in Thrombosis and Hemostasis》 - 2025,51(1) - 18~22 - 共5页

摘要: hemophilia A (PwHA) with severe bleeding phenotype is | The mainstay of treatment for persons with |  prophylaxis. The pharmacokinetic (PK) profile of native |  factor VIII (FVIII) imposes the need for rather |  frequent intravenous injections to ensure effective
关键词: hemophilia A |  factor VIII |  EHL-FVIII |  efanesoctocog alfa |  prophylaxis
检索条件hemophilia
  • 检索词扩展

NSTL主题词

  • NSTL学科导航